Finance

Molecular medicine-focused company reports results for first half of 2005

Published in Vaccine Weekly, September 14th, 2005

During the first 6 months of 2005, Mologen reports investments in an expansion of the dSLIM segment and a better capitalization.

The consolidated financial statement, compiled with IFRS, shows Mologen to have had a business volume of EUR.4 million (US$.49 million) in the first half of 2005. The volume is expected to increase significantly in the second half year, due to the revenues anticipated from cell- and gene-therapy centers. In the first half of 2004, the business volume was EUR1.1 million (US$1.35 million).

The operational cash flow was EUR-1.7 million (US.-$2.09 million) during the first half of 2005 due to increased activities in research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-09-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry